Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. (HealthDay News) — For patients with inadequately controlled type 2 diabetes ...

Painful diabetic neuropathy was associated with lower quality of life and higher rates of depression and anxiety than painless diabetic neuropathy.

(HealthDay News) — Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia (BPH) surgery, according to a ...

(HealthDay News) — The U.S. Senate has confirmed the appointment of Mehmet Oz, M.D., to head the Centers for Medicare & Medicaid Services (CMS), according to a report from The New York Times.

Compared to the general population, individuals with incident hospital-based cannabis use disorder care have an increased risk of death.

In-hospital mortality in patients with AMI can be predicted with a risk-standardized model that includes patient factors, such as age and cardiogenic shock.

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

“AI can enhance clinical decision-making for common acute symptoms in a virtual urgent care setting,” the authors write. “Thoughtful integration of AI into clinical practice, combining its strengths ...

Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.